Header Logo

Connection

MANJUSHA GAGLANI to Middle Aged

Back to Details
This is a "connection" page, showing publications MANJUSHA GAGLANI has written about Middle Aged.
MANJUSHA GAGLANI
Connection Strength
1.072
Middle Aged
  1. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021 07 22; 385(4):320-329.
    View in: PubMed
    Score: 0.048
  2. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 02; 70(13):495-500.
    View in: PubMed
    Score: 0.047
  3. Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. Vaccine. 2016 Feb 10; 34(7):981-8.
    View in: PubMed
    Score: 0.033
  4. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis. 2016 May 15; 213(10):1546-56.
    View in: PubMed
    Score: 0.033
  5. Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine. J Infect Dis. 2014 Jun 01; 209(11):1705-14.
    View in: PubMed
    Score: 0.028
  6. Subjective social status predicts wintertime febrile acute respiratory illness among women healthcare personnel. Health Psychol. 2014 Mar; 33(3):282-91.
    View in: PubMed
    Score: 0.027
  7. Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers. J Infect Dis. 2025 Mar 17; 231(3):665-676.
    View in: PubMed
    Score: 0.015
  8. Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27; 74(6):83-90.
    View in: PubMed
    Score: 0.015
  9. Effectiveness of the Original Monovalent Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination Series Against Hospitalization for COVID-19-Associated Venous Thromboembolism. J Infect Dis. 2025 Feb 20; 231(2):378-385.
    View in: PubMed
    Score: 0.015
  10. COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United States, 2019-2022. Vaccine. 2025 Feb 27; 48:126806.
    View in: PubMed
    Score: 0.015
  11. Vaccine effectiveness against influenza-associated hospitalizations in adults with liver disease, 2015-2020: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). Hum Vaccin Immunother. 2025 Dec; 21(1):2457205.
    View in: PubMed
    Score: 0.015
  12. Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance. PLoS One. 2024; 19(12):e0306953.
    View in: PubMed
    Score: 0.015
  13. Reduced Effectiveness of Repeat Influenza Vaccination: Distinguishing Among Within-Season Waning, Recent Clinical Infection, and Subclinical Infection. J Infect Dis. 2024 Dec 16; 230(6):1309-1318.
    View in: PubMed
    Score: 0.015
  14. Molecular features of the serological IgG repertoire elicited by egg-based, cell-based, or recombinant haemagglutinin-based seasonal influenza vaccines: a comparative, prospective, observational cohort study. Lancet Microbe. 2025 Feb; 6(2):100935.
    View in: PubMed
    Score: 0.015
  15. Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023. Vaccine. 2025 Jan 01; 43(Pt 2):126492.
    View in: PubMed
    Score: 0.015
  16. Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022-August 2023. Influenza Other Respir Viruses. 2024 11; 18(11):e70027.
    View in: PubMed
    Score: 0.015
  17. Elevated body mass index is not significantly associated with reduced influenza vaccine effectiveness. Sci Rep. 2024 09 13; 14(1):21466.
    View in: PubMed
    Score: 0.015
  18. Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022. J Infect Dis. 2024 Jul 25; 230(1):45-54.
    View in: PubMed
    Score: 0.015
  19. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
    View in: PubMed
    Score: 0.015
  20. Hybrid Immunity and SARS-CoV-2 Antibodies: Results of the HEROES-RECOVER Prospective Cohort Study. Clin Infect Dis. 2024 07 19; 79(1):96-107.
    View in: PubMed
    Score: 0.015
  21. Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021-June 2022. Influenza Other Respir Viruses. 2024 07; 18(7):e13339.
    View in: PubMed
    Score: 0.015
  22. Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017-2018. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2354013.
    View in: PubMed
    Score: 0.015
  23. Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023. Influenza Other Respir Viruses. 2024 06; 18(6):e13342.
    View in: PubMed
    Score: 0.015
  24. Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023. Clin Infect Dis. 2024 04 10; 78(4):1056-1064.
    View in: PubMed
    Score: 0.014
  25. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Netw Open. 2024 04 01; 7(4):e244954.
    View in: PubMed
    Score: 0.014
  26. Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With COVID-19-VISION Network, 10 States, June 2021-March 2023. Clin Infect Dis. 2024 02 17; 78(2):338-348.
    View in: PubMed
    Score: 0.014
  27. Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022. Clin Infect Dis. 2023 08 22; 77(4):547-557.
    View in: PubMed
    Score: 0.014
  28. Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022. Clin Infect Dis. 2023 03 21; 76(6):1030-1037.
    View in: PubMed
    Score: 0.013
  29. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023 03 01; 6(3):e232598.
    View in: PubMed
    Score: 0.013
  30. Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. Clin Infect Dis. 2023 02 08; 76(3):e460-e468.
    View in: PubMed
    Score: 0.013
  31. Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. BMJ. 2022 10 11; 379:e072065.
    View in: PubMed
    Score: 0.013
  32. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Clin Infect Dis. 2022 05 03; 74(9):1515-1524.
    View in: PubMed
    Score: 0.013
  33. Interim Estimates of 2021-22 Seasonal Influenza Vaccine Effectiveness - United States, February 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 11; 71(10):365-370.
    View in: PubMed
    Score: 0.013
  34. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
    View in: PubMed
    Score: 0.012
  35. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 28; 71(4):118-124.
    View in: PubMed
    Score: 0.012
  36. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 21; 71(4):139-145.
    View in: PubMed
    Score: 0.012
  37. Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults. Clin Infect Dis. 2021 12 06; 73(11):e4353-e4360.
    View in: PubMed
    Score: 0.012
  38. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021 11 23; 326(20):2043-2054.
    View in: PubMed
    Score: 0.012
  39. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.012
  40. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.012
  41. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 24; 70(38):1337-1343.
    View in: PubMed
    Score: 0.012
  42. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021 10 07; 385(15):1355-1371.
    View in: PubMed
    Score: 0.012
  43. Influenza Vaccine Effectiveness Against Hospitalization in the United States, 2019-2020. J Infect Dis. 2021 09 01; 224(5):813-820.
    View in: PubMed
    Score: 0.012
  44. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27; 70(34):1156-1162.
    View in: PubMed
    Score: 0.012
  45. Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2018-2019, US Hospitalized Adult Influenza Vaccine Effectiveness Network. J Infect Dis. 2021 07 02; 224(1):151-163.
    View in: PubMed
    Score: 0.012
  46. Influenza vaccine effectiveness among outpatients in the US Influenza Vaccine Effectiveness Network by study site 2011-2016. Influenza Other Respir Viruses. 2020 07; 14(4):380-390.
    View in: PubMed
    Score: 0.011
  47. Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 21; 69(7):177-182.
    View in: PubMed
    Score: 0.011
  48. Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018-2019 Season. J Infect Dis. 2020 01 01; 221(1):8-15.
    View in: PubMed
    Score: 0.011
  49. Paid Leave and Access to Telework as Work Attendance Determinants during Acute Respiratory Illness, United States, 2017-2018. Emerg Infect Dis. 2020 01; 26(1).
    View in: PubMed
    Score: 0.011
  50. Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season. Clin Infect Dis. 2019 11 13; 69(11):1845-1853.
    View in: PubMed
    Score: 0.011
  51. Prevention of Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). J Infect Dis. 2019 09 13; 220(8):1265-1275.
    View in: PubMed
    Score: 0.011
  52. Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season. Clin Infect Dis. 2019 05 17; 68(11):1798-1806.
    View in: PubMed
    Score: 0.010
  53. Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011-2017. Clin Infect Dis. 2019 05 02; 68(10):1616-1622.
    View in: PubMed
    Score: 0.010
  54. Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness - United States, February 2019. MMWR Morb Mortal Wkly Rep. 2019 Feb 15; 68(6):135-139.
    View in: PubMed
    Score: 0.010
  55. Hospitalization following outpatient medical care for influenza: US influenza vaccine effectiveness network, 2011-12-2015-16. Influenza Other Respir Viruses. 2019 03; 13(2):133-137.
    View in: PubMed
    Score: 0.010
  56. Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016. Vaccine. 2018 12 18; 36(52):8047-8053.
    View in: PubMed
    Score: 0.010
  57. Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. J Infect Dis. 2018 06 20; 218(2):189-196.
    View in: PubMed
    Score: 0.010
  58. Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons. JAMA Netw Open. 2018 06 01; 1(2):e180243.
    View in: PubMed
    Score: 0.010
  59. Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons-United States, 2011-2016. Clin Infect Dis. 2018 03 19; 66(7):1035-1041.
    View in: PubMed
    Score: 0.010
  60. Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. Vaccine. 2018 02 28; 36(10):1272-1278.
    View in: PubMed
    Score: 0.009
  61. Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018. MMWR Morb Mortal Wkly Rep. 2018 Feb 16; 67(6):180-185.
    View in: PubMed
    Score: 0.009
  62. Burden of medically attended influenza infection and cases averted by vaccination - United States, 2013/14 through 2015/16 influenza seasons. Vaccine. 2018 01 25; 36(4):467-472.
    View in: PubMed
    Score: 0.009
  63. Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season. N Engl J Med. 2017 08 10; 377(6):534-543.
    View in: PubMed
    Score: 0.009
  64. Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017. MMWR Morb Mortal Wkly Rep. 2017 Feb 17; 66(6):167-171.
    View in: PubMed
    Score: 0.009
  65. 2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. Clin Infect Dis. 2016 Dec 15; 63(12):1564-1573.
    View in: PubMed
    Score: 0.009
  66. Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015. J Infect Dis. 2016 10 01; 214(7):1010-9.
    View in: PubMed
    Score: 0.008
  67. Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013. Clin Infect Dis. 2016 Feb 15; 62(4):448-455.
    View in: PubMed
    Score: 0.008
  68. Factors associated with real-time RT-PCR cycle threshold values among medically attended influenza episodes. J Med Virol. 2016 Apr; 88(4):719-23.
    View in: PubMed
    Score: 0.008
  69. Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons. Vaccine. 2015 Sep 22; 33(39):5181-7.
    View in: PubMed
    Score: 0.008
  70. Use of influenza antiviral medications among outpatients at high risk for influenza-associated complications during the 2013-2014 influenza season. Clin Infect Dis. 2015 Jun 01; 60(11):1677-80.
    View in: PubMed
    Score: 0.008
  71. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep. 2015 Jan 16; 64(1):10-5.
    View in: PubMed
    Score: 0.008
  72. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015 May 15; 211(10):1529-40.
    View in: PubMed
    Score: 0.008
  73. Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season. Clin Infect Dis. 2014 Sep 15; 59(6):774-82.
    View in: PubMed
    Score: 0.007
  74. Barriers and facilitators to influenza vaccination and vaccine coverage in a cohort of health care personnel. Am J Infect Control. 2014 Apr; 42(4):371-5.
    View in: PubMed
    Score: 0.007
  75. Comparison of laboratory-confirmed influenza and noninfluenza acute respiratory illness in healthcare personnel during the 2010-2011 influenza season. Infect Control Hosp Epidemiol. 2014 May; 35(5):538-46.
    View in: PubMed
    Score: 0.007
  76. Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014. MMWR Morb Mortal Wkly Rep. 2014 Feb 21; 63(7):137-42.
    View in: PubMed
    Score: 0.007
  77. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb; 58(3):319-27.
    View in: PubMed
    Score: 0.007
  78. Changes in self-rated health and subjective social status over time in a cohort of healthcare personnel. J Health Psychol. 2014 Sep; 19(9):1185-96.
    View in: PubMed
    Score: 0.007
  79. The expected emotional benefits of influenza vaccination strongly affect pre-season intentions and subsequent vaccination among healthcare personnel. Vaccine. 2012 May 21; 30(24):3557-65.
    View in: PubMed
    Score: 0.006
  80. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis. 2010 Mar 17; 10:71.
    View in: PubMed
    Score: 0.005
  81. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007 Sep; 120(3):e553-64.
    View in: PubMed
    Score: 0.005
  82. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005 Feb 18; 23(13):1540-8.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.